TY  - JOUR
AU  - Schmidt, Martina
AU  - Goldschmidt, Siri
AU  - Kreutz, Charlotte
AU  - Müller, Jana
AU  - Schneeweiss, Andreas
AU  - May, Anne M
AU  - Rosenberger, Friederike
AU  - Wiskemann, Joachim
AU  - Steindorf, Karen
TI  - Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: The randomized controlled BENEFIT trial.
JO  - Journal of sport and health science
VL  - 14
SN  - 2095-2546
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01125
SP  - 101064
PY  - 2025
N1  - #EA:C110#LA:C110# / Volume 14, December 2025, 101064
AB  - The potential of exercise as a concurrent therapy for actively treated primary tumors has been suggested by emerging preclinical and observational studies. However, clinical trials regarding this question are scarce. Therefore, we conducted a randomized controlled trial investigating the effects of aerobic or resistance exercise concomitant to neoadjuvant chemotherapy (NACT) on tumor size.IN THE BENEFIT STUDY (GERMAN TITLE: BEwegung bei NEoadjuvanter Chemotherapie zur Verbesserung der FITness), patients with breast cancer scheduled for NACT were randomly assigned to supervised resistance training (RT, n = 60) or aerobic training (AT, n = 60) twice weekly during NACT or to a waitlist control group (WCG, n = 60). The primary outcome, 'change in tumor size', as well as the secondary clinical outcomes pathologic complete response (pCR), type of surgery (breast conserving/mastectomy), axillary lymph node dissection (ALND, yes/no), premature discontinuation of chemotherapy (yes/no), and relative dose intensity (RDI) were derived from clinical records. Due to the highly skewed distribution, the primary outcome was categorized. Multiple (ordinal) logistic regression analyses were performed.Overall, there was no significant difference in post-intervention tumor size between RT or AT and WCG. However, there was a significant effect modification by hormone receptor (HR) status (pinteraction = 0.030). Among patients with HR+ tumors, results suggest a beneficial effect of AT on tumor shrinkage (odds ratio (OR) = 2.37, 95
KW  - Clinical cancer outcomes (Other)
KW  - Neoadjuvant chemotherapy (Other)
KW  - Pathologic complete response (Other)
KW  - Supervised exercise (Other)
KW  - Tumor response (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40447136
DO  - DOI:10.1016/j.jshs.2025.101064
UR  - https://inrepo02.dkfz.de/record/301741
ER  -